First-line treatment of metastatic melanoma: role of nivolumab.

Loading...
Thumbnail Image

Date

2017

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

154
views
179
downloads

Citation Stats

Abstract

Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape with increased survival rates and the real possibility that long-term disease control is achievable. Advances in immune modulators, including cytotoxic T-lymphocyte antigen-4 and programmed death-1 based treatments, have been an integral part of this success. In this article, we review previous and recent therapeutic developments for metastatic melanoma patients. We discuss advances in immunotherapy while focusing on the use of nivolumab alone and in combination with other agents, including ipilimumab in advanced melanoma. One major goal in melanoma research is to optimize combination strategies allowing for more patients to experience benefit while minimizing toxicity. A better understanding of the optimal sequencing, combinations, and mechanisms underlying the development of resistance may provide evidence for rational clinical trial designs of novel immunotherapy strategies in melanoma and other cancer subtypes.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.2147/ITT.S110479

Publication Info

Force, Jeremy, and April Ks Salama (2017). First-line treatment of metastatic melanoma: role of nivolumab. Immunotargets Ther, 6. pp. 1–10. 10.2147/ITT.S110479 Retrieved from https://hdl.handle.net/10161/15631.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Salama

April Kelly Scott Salama

Associate Professor of Medicine

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.